Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment
Authors:
- Emanuela OrsiEOEmanuela Orsi
- Enzo BonoraEBEnzo Bonora
- Anna SoliniAnna Solini
- Cecilia FondelliCFCecilia Fondelli
- Roberto TrevisanRTRoberto Trevisan
- Monica VedovatoMVMonica Vedovato
- Franco CavalotFCFranco Cavalot
- Gianpaolo ZerbiniGZGianpaolo Zerbini
- Susanna MoranoSMSusanna Morano
- Antonio NicolucciANAntonio Nicolucci
- Giuseppe PennoGPGiuseppe Penno
- Giuseppe PuglieseGiuseppe Pugliese
Open Access
- 17 January 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (1) , 246
Abstract
The increased mortality reported with intensive glycaemic control has been attributed to an increased risk of treatment-related hypoglycaemia. This study investigated the relationships of haemoglobin (Hb) A1c, anti-hyperglycaemic treatment, and potential risks of adverse effects with all-cause mortality in patients with type 2 diabetes. Patients (n = 15,773) were stratified into four categories according to baseline HbA1c and then assigned to three target categories, based on whether HbA1c was ≤0.5% below or above (on-target), >0.5% below (below-target) or >0.5% above (above-target) their HbA1c goal, personalized according to the number of potential risks among age > 70 years, diabetes duration > 10 years, advanced complication(s), and severe comorbidity (ies). The vital status was retrieved for 15,656 patients (99.26%). Over a 7.4-year follow-up, mortality risk was increased among patients in the highest HbA1c category (≥8.5%) (adjusted hazard ratio, 1.34 (95% confidence interval, 1.22–1.47), p < 0.001) and those above-target (1.42 (1.29–1.57), p < 0.001). Risk was increased among individuals in the lowest HbA1c category (p = 0.01 and 1.10 (1.01–1.22), p = 0.04, respectively). These data suggest the importance of setting both upper and lower personalized HbA1c goals to avoid overtreatment in high-risk individuals with type 2 diabetes treated with agents causing hypoglycaemia.Keywords
Funding Information
- Fondazione Diabete Ricerca (N/A)
- Diabetes, Endocrinology and Metabolism Foundation (N/A)
- Eli Lilly and Company (N/A)
- Sigma-Tau Pharmaceuticals (N/A)
- Chiesi Farmaceutici (N/A)
- Takeda Pharmaceutical Company (N/A)
- Boehringer Ingelheim (N/A)
This publication has 33 references indexed in Scilit:
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Diverging Association of Reduced Glomerular Filtration Rate and Albuminuria With Coronary and Noncoronary Events in Patients With Type 2 DiabetesDiabetes Care, 2011
- Glycemic Control, Complications, and Death in Older Diabetic PatientsDiabetes Care, 2011
- The effect of intensive glycaemic control on cardiovascular outcomesDiabetes, Obesity and Metabolism, 2010
- Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD TrialDiabetes Care, 2010
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Standards of Medical Care in Diabetes—2008Diabetes Care, 2008